Introduction: Six years ago (in September 2003), the fifth Haemopoietic Stem Cell Transplantation Centre of Hungary began its activity. This centre registered as the No. 648 sub-centre of the European Blood and Marrow Transplantation Committee.
Objectives: To meet the demand for transplantation of haemopoietic stem cells in the North-Eastern regions of Hungary and to establish active connections with the domestic and international centres.
Methods: The interventions were performed in accordance with international criteria.
Results: Up to now 150 autologous stem cell transplantations were performed including 74 patients with multiple myeloma, 43 with non-Hodgkin lymphoma, one with chronic lymphoid leukaemia, 27 with Hodgkin's disease, four patients with autoimmune disease, and one with leiomyosarcoma. Survival rates were similar to Hungarian and international data. The centre has taken a role also in other activities using stem cell therapy at the University of Debrecen (dendritic cell-based vaccine program, stem cell therapy in myocardial infarction, peripheral arterial disease, and autoimmune diseases). This centre performed the most use of conditioning protocol Zevalin (ibritumomab tiuxetan), bischloroethylnitrosourea, etoposide, cytosine arabinoside, and melphalan (Z-BEAM) in patients with non-Hodgkin lymphoma in Hungary (ten patients were treated).
[1]. Gy. Petrányi J. Bobory 1967 Treatment of myeloid leukaemias with Myelobromol (in Hung.) Orv. Hetil. 108 689–692.
[2]. C. W. Jackson 1973 Cholinesterase as a possible marker for early cells of megakaryocytic series Blood 42 413–421.
[3]. A. Kiss J. Jakó B. Telek et al.1980 Lymphoid leukaemia transplantation experiments with (AKR) Lati X C3H/He-mg Lati/F1 hibrid mouse (in Hung.) Magy. Onkol. 24 243–252.
[4]. A. Kiss J. L. Iványi P. Nagy et al.1984 Complex study of the effect of vincristine on thrombocytopoiesis in mice Cell. Tiss. K. 17 297–298.
[5]. Kiss, A.: Megakaryocyte progenitor-cells in experimental and human environments (in Hung.). PhD thesis. Debrecen, 1987.
[6]. E. Kelemen 1973 Recovery from chronic idiopathic bone marrow aplasia of a young mother after intravenous injection of unprocessed cells from the liver and yolk sac of her 22 mm CR-length embryo Preliminary report. Scand. J. Haemat. 10 305–308.
[7]. A. Barta A. Batai E. Torbagyi et al.1998 Haemopoietic cell transplantation activity and result: a single institution experience Bone Marrow Transplantation 22 60–62.
[8]. K. Pálóczi A. Barta A. Poros 2004 Blood producing stem cells in the therapy (in Hung.) Magyar Tudomány 3 337–341.
[9]. A. Gratwohl H. Baldomero K. Frauendorfer et al.2006 Activity survey 2004 and changes in disease indication over the last 15 years Bone Marrow Transplant. 37 1069–1085.
[10]. A. Gratwohl H. Baldomero K. Frauendorfer et al.2007 The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products Bone Marrow Transplant. 38 1–19.
[11]. A. Kiss Gy. Reményi R. Szász et al.2007 After the 100th. autologous peripheral haemopoietic stem cell transplantation in the 2nd Department of the Medicine, University of Debrecen, Hungary. Leukemia Res. 31 107–108.
[12]. G. Reményi A. Kiss P. Batár et al.2007 Zevalin BEAM conditioning therapy for autologous peripheral stem cell transplantation (PSCT) in patients with follicular non-Hodgkin lymphoma Leukemia Res. 31 106–107.
[13]. A. Kiss Gy. Reményi P. Batár et al.2008 Zevalin-BEAM conditioning therapy for autologous peripheral stem cell transplantation, in patients with follicular non-Hodgkin lymphomas (in Hung.) Orvostudományi Értesítő 81 108–111.
[14]. L. Balogh I. Czuriga J. Hunyadi et al.2007 The effect of CD34+ stem cells of bone marrow origin on the function of left chamber following myocardial infarction (in Hung.) Orv.Hetil. 148 243–249.
[15]. Z. Boda M. Udvardy K. Farkas et al.2008 The result of autologous stem cell therapy of bone marrow origin in advanced peripheral arterial vascular diseases (in Hung.) Orv. Hetil. 149 531–540.
[16]. L. Váróczy Illés E. Kiss et al.2008 The application of high dose chemotherapy and autologous CD34+ stem cell transplantation in the treatment of severe adult, therapy refrataer, polysystemic autoimmune diseases. First Hungarian observations Orv. Hetil. 149 1405–1412.
[17]. A. Gratwohl 2008 Principles of conditioning J. Apperley E. Carreras E. Gluckman A. Gratwohl T. Masszi The EBMT Handbook. 5th Edition of Haematopoietic stem cell transplantation Revised edition BMT and ESH, Forum Service Editore Genoa, Italy 129–144.
[18]. T. Masszi 2008 Supportive care J. Apperley E. Carreras E. Gluckman A. Gratwohl T. Masszi The EBMT Handbook Revised edition EBMT and ESH, Forum Service Editore Genoa, Italy 165–178.
[19]. R. M. Szydlo 2008 Statistical evaluation of HSCT date J. Apperley E. Carreras E. Gluckman A. Gratwohl T. Masszi The EBMT Handbook Revised edition EBMT and ESH, Forum Service Editore Genoa, Italy 329–339.
[20]. S. R. Fanning L. Rybicki M. Kalaycio et al.2006 Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies Br. J. Haematol. 135 374–381.